Granahan Investment Management LLC Decreases Stock Position in Certara, Inc. (NASDAQ:CERT)

Granahan Investment Management LLC decreased its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 20.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 239,224 shares of the company's stock after selling 63,257 shares during the quarter. Granahan Investment Management LLC owned approximately 0.15% of Certara worth $2,548,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Venturi Wealth Management LLC increased its holdings in Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after purchasing an additional 2,509 shares during the period. Wells Fargo & Company MN lifted its holdings in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. bought a new stake in shares of Certara in the 4th quarter worth approximately $47,000. Blue Trust Inc. increased its stake in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after buying an additional 822 shares during the period. Finally, ANTIPODES PARTNERS Ltd lifted its stake in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after acquiring an additional 3,656 shares during the period. 73.96% of the stock is owned by institutional investors.

Certara Stock Up 2.5%

Certara stock traded up $0.30 during mid-day trading on Friday, hitting $11.92. The company had a trading volume of 507,497 shares, compared to its average volume of 1,303,737. Certara, Inc. has a 12 month low of $8.64 and a 12 month high of $17.76. The company has a market capitalization of $1.93 billion, a PE ratio of -59.67, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The stock's 50 day moving average price is $11.70 and its two-hundred day moving average price is $11.71. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. William Blair restated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. JMP Securities restated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Stephens reiterated an "overweight" rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Finally, KeyCorp upped their target price on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.